The Journal of the American Medical Association this week published a commentary, “Psychiatrists’ Relationships With Pharmaceutical Companies: Part of the Problem or Part of the Solution?” by the chief of the National Institute of Mental Health.
On his blog, psychiatrist Daniel Carlat praises the “power (and courage) of the country’s chief psychiatrist calling his own profession out on the carpet for bad behavior.”
But on the Health Care Renewal blog, Dr. Bernard Carroll, past chair of the Duke psychiatry department, writes:
“With ludicrous optimism and a series of straw man discussions, Dr. Insel (NIMH chief) makes the case that things are not really as bad as they seemed to be or, if they were, then other specialty physicians were doing much the same things. Dr. Insel needs to recalibrate his ethical compass.
Why is an NIH Institute Director issuing this apologia for the corruption of academic psychiatry? Does he not have better things to do, such as ensuring that longstanding NIH regulations on conflict of interest are enforced?”
Read the entire blog posts cited above to get a fuller flavor of the dispute.